Nevro Corp. has issued a consensus statement supporting high-frequency (10 kHz) Spinal Cord Stimulation (SCS) for refractory PDN. The Worldwide Initiative for Diabetes Education’s diabetes, Pain in Diabetic Neuropathy, and health services experts advised this announcement.
Pain in Diabetic Neuropathy: Nevro Sparks Hope on 10 kHz Spinal Cord Stimulation Therapy (Photo from Health Awareness)
Global Experts Confirm High-Frequency SCS, Particularly Nevro’s HFX, as Effective Treatment for Refractory Pain in Diabetic Neuropathy (PDN)
The consensus statement in Diabetes Research and Clinical Practice emphasizes the efficacy of high-frequency SCS in treating Pain in Diabetic Neuropathy PDN symptoms that do not respond to the first treatment. A global interdisciplinary panel at the WorldWIDE Diabetes Virtual Global Summit in December 2022 produced the consensus declaration. High-frequency SCS therapy is recommended for PDN symptoms untreated by first- and second-line therapies. These recommendations emphasize the need for SCS therapy, specifically Nevro’s HFX for PDN, in treating refractory PDN symptoms.
Dr. David Caraway, Nevro’s Chief Medical Officer, stressed the relevance of findings from the SENZA-PDN RCT, the biggest RCT evaluating SCS for PDN, in validating high-frequency (10 kHz) SCS for this patient population. High-frequency SCS has been shown effective in treating difficult Pain in Diabetic Neuropathy PDN symptoms thanks to the SENZA-PDN experiment.
Dr. Erika Petersen, SENZA-PDN’s lead primary investigator, and neurosurgery professor, noted that high-frequency SCS improved pain alleviation, quality of life, sleep, and neurological function during the experiment. Her findings suggest that high-frequency SCS may improve PDN results.
READ ALSO: Medical Marijuana Market In Europe Soars With 19.0%: Dominance In Pain Management Applications
Nevro’s Innovative 10 kHz Therapy™ Earns Global Recognition for Effectively Relieving Pain in Diabetic Neuropathy (PDN)
Pain in Diabetic Neuropathy PDN affects about 50% of type 2 diabetics and can lower quality of life. Traditional oral painkillers may be ineffective and have unacceptable adverse effects. Therefore, PDN patients have lower health-related quality of life and more problems like sleep disturbances, sadness, and anxiety.
The only FDA-approved high-frequency paresthesia-free SCS system for treating Pain in Diabetic Neuropathy PDN is Nevro’s 10 kHz Therapy™. The consensus statement confirms Nevro’s unique technology’s pain-reduction and neurological-function-restoring effects on Pain in Diabetic Neuropathy PDN patients. The recognition from global experts reinforces Nevro’s dedication to developing chronic pain treatment solutions.
In addition to the consensus statement, the American Diabetes Association, German Diabetes Association, and American Association of Clinical Endocrinologists endorse high-frequency SCS for Pain in Diabetic Neuropathy PDN treatment.
READ ALSO: Transforming How We Treat Cancer
